MX2015007688A - Composicion de vacunas para uso en poblaciones inmunocomprometidas. - Google Patents

Composicion de vacunas para uso en poblaciones inmunocomprometidas.

Info

Publication number
MX2015007688A
MX2015007688A MX2015007688A MX2015007688A MX2015007688A MX 2015007688 A MX2015007688 A MX 2015007688A MX 2015007688 A MX2015007688 A MX 2015007688A MX 2015007688 A MX2015007688 A MX 2015007688A MX 2015007688 A MX2015007688 A MX 2015007688A
Authority
MX
Mexico
Prior art keywords
immuno
vaccine composition
vaccine
compromised populations
directed
Prior art date
Application number
MX2015007688A
Other languages
English (en)
Spanish (es)
Inventor
Hans Arwidsson
Anna-Karin Maltais
Original Assignee
Eurocine Vaccines Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Vaccines Ab filed Critical Eurocine Vaccines Ab
Publication of MX2015007688A publication Critical patent/MX2015007688A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
MX2015007688A 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas. MX2015007688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077007 WO2014095944A1 (en) 2012-12-17 2013-12-17 Vaccine composition for use in immuno-compromised populations

Publications (1)

Publication Number Publication Date
MX2015007688A true MX2015007688A (es) 2015-09-07

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007688A MX2015007688A (es) 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas.
MX2015007753A MX2015007753A (es) 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015007753A MX2015007753A (es) 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos.

Country Status (12)

Country Link
US (2) US11065325B2 (https=)
EP (4) EP2742952A1 (https=)
JP (3) JP2016502997A (https=)
KR (3) KR20150132092A (https=)
CN (3) CN104884085A (https=)
AU (2) AU2013360890B2 (https=)
BR (2) BR112015014243A8 (https=)
CA (2) CA2895023A1 (https=)
HK (2) HK1212611A1 (https=)
MX (2) MX2015007688A (https=)
RU (2) RU2661408C2 (https=)
WO (2) WO2014095943A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101857839B1 (ko) * 2010-09-30 2018-05-14 유로씨네 백신즈 에이비 개선된 백신 조성물들
KR20230154072A (ko) 2014-09-26 2023-11-07 세퀴러스 유케이 리미티드 면역손상된 대상체의 백신 접종
EP3197487B1 (en) 2014-09-26 2022-08-03 Seqirus UK Limited Vaccination of immunocompromised subjects
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135520B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
HUE069425T2 (hu) * 2020-04-16 2025-03-28 Bayer Ag Hatóanyag-kombinációk és azokat tartalmazó fungicid készítmények
HUE069397T2 (hu) * 2020-04-16 2025-03-28 Bayer Ag Hatóanyag-kombinációk és azokat tartalmazó fungicid készítmények
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
EP4463180A2 (en) * 2022-01-10 2024-11-20 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
ES2352671T3 (es) 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
CA2611721C (en) 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
JP2011506290A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2293814A4 (en) 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
KR101857839B1 (ko) 2010-09-30 2018-05-14 유로씨네 백신즈 에이비 개선된 백신 조성물들

Also Published As

Publication number Publication date
BR112015014174A2 (pt) 2017-07-11
AU2013360889C1 (en) 2017-06-08
EP3431101A1 (en) 2019-01-23
AU2013360890A1 (en) 2015-07-02
US20150306204A1 (en) 2015-10-29
MX2015007753A (es) 2016-01-08
EP2931308B1 (en) 2018-10-10
US20150306205A1 (en) 2015-10-29
JP2016502997A (ja) 2016-02-01
AU2013360889B2 (en) 2016-12-01
RU2661407C2 (ru) 2018-07-16
RU2015129028A (ru) 2017-01-23
JP2016502996A (ja) 2016-02-01
EP2742952A1 (en) 2014-06-18
US11065325B2 (en) 2021-07-20
BR112015014243A8 (pt) 2019-10-08
RU2015129077A (ru) 2017-01-23
CN112826929A (zh) 2021-05-25
BR112015014243A2 (pt) 2017-07-11
CA2895028A1 (en) 2014-06-26
WO2014095944A1 (en) 2014-06-26
HK1213492A1 (zh) 2016-07-08
JP2019112448A (ja) 2019-07-11
KR20150132093A (ko) 2015-11-25
EP2931307B1 (en) 2018-09-12
EP2931307A1 (en) 2015-10-21
HK1212611A1 (zh) 2016-06-17
EP2931308A1 (en) 2015-10-21
AU2013360890B2 (en) 2017-04-13
KR20150132092A (ko) 2015-11-25
WO2014095943A1 (en) 2014-06-26
CN104884085A (zh) 2015-09-02
CN104870010A (zh) 2015-08-26
AU2013360889A1 (en) 2015-07-02
RU2661408C2 (ru) 2018-07-16
CA2895023A1 (en) 2014-06-26
KR20210007042A (ko) 2021-01-19

Similar Documents

Publication Publication Date Title
MX2015007688A (es) Composicion de vacunas para uso en poblaciones inmunocomprometidas.
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
EA028928B9 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
MX360056B (es) Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
JO3204B1 (ar) 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IN2013MU01749A (https=)
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
MX2015000446A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
EA201290956A1 (ru) Вакцина против вич
IN2014MN01907A (https=)
BR112012013199A8 (pt) Composto, composição farmacêutica, e , uso de um composto
MX2015005112A (es) Composicion inmunogenica contra la aeromonas hydrophila.
BR112013023354A2 (pt) vacina para rinite equina
BR112015002984A2 (pt) composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido cítrico.
UA117672C2 (uk) Антибактеріальні сполуки
BR112015003074A2 (pt) composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido etilenodiaminatetra-acético.